Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Роль преконцепционной эндотелиальной дисфункции в развитии акушерских осложнений

https://doi.org/10.33667/2078-5631-2019-1-1(376)-53-58

Полный текст:

Аннотация

В статье освещены патогенетические механизмы формирования эндотелиальной дисфункции и ее роль в возникновении гестационных осложнений. Рассмотрены основные задачи прегравидарной подготовки пациентов с заболеваниями, ассоциированными с эндотелиальной дисфункцией. Подчеркивается актуальность раннего выявления факторов риска гестационных осложнений, обусловленных дисфункцией эндотелия, и описываются методы ее косвенной оценки. Приведен перечень мероприятий, направленных на предотвращение клинической реализации эндотелиальной дисфункции, и описаны возможности ее терапевтической коррекции.

Об авторе

И. В. Кузнецова
ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова (Сеченовский университет)» Минздрава России
Россия


Список литературы

1. Chatterjee Sh. Endothelial Mechanotransduction, Redox Signaling and the Regulation of Vascular Inflammatory Pathways. Front Physiol. 2018; 9: 524.

2. Daiber A, Steven S, Weber A, et al. Targeting vascular (endothelial) dysfunction. Br J Pharmacol 2017; 174 (12): 1591-1619.

3. Butt M, Dwivedi G, Blann A, Khair O, Lip GY. Endothelial dysfunction: Methods of assessment & implications for cardiovascular diseases. Curr Pharm Des. 2010; 16: 3442-3454.

4. Gandley RE, Althouse A, Jeyabalan A, et al. Low Soluble Syndecan-1 Precedes Preeclampsia PLoS One. 2016; 11 (6): e0157608.

5. Garrido-Gomez T, Ona K, Kapidzic M, et al. Severe pre-eclampsia is associated with alterations in cytotrophoblasts of the smooth chorion. Development2017; 144 (5): 767-777.

6. Макаров О. В., Волкова Е. В., Винокурова И. Н., Джохадзе Л. С. Лечение артериальной гипертензии у беременных. Проблемы репродукции. 2011; 6: 87-92.

7. Heimrath J, Paprocka M, Czekanski A, et al. Pregnancy-induced hypertension is accompanied by decreased number of circulating endothelial cells and circulating endothelial progenitor cells. Arch Immunol Ther Exp (Warsz). 2014; 62 (4): 353-356.

8. Lash GE, Ansari T, Bishof P. IFPA Meeting 2008 Workshop Report. Placenta 2009; 30 (Suppl A): S4-14.

9. Myatt L, Muralimanoharan S, Maloyan A. Effect of preeclampsia on placental function: influence of sexual dimorphism, microRNA’s and mitochondria. Adv Exp Med Biol 2014; 814: 133-146.

10. Possomato-Vieira JS, Khalil RA. Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia. Adv Pharmacol 2016; 77: 361-431.

11. Shi Z, Long W, Zhao C, et al. Comparative proteomics analysis suggests that placental mitochondria are involved in the development of pre-eclampsia. PLoS One 2013; 8 (5): e64351.

12. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Ann Rev Pathol. 2010; 5:173-192.

13. Villa PM, Kajantie E, Raikkonen K, et al. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. BJOG. 2013; 120 (1): 64-74.

14. Доброхотова Ю. Э., Боровкова Е. И. Прегравидарная подготовка: цели, задачи, возможности. Эффективная фармакотерапия 2017; 13: 14-18.

15. Moos MK, Dunlop AL, Jack BW, et al. Healthier women, healthier reproductive outcomes: recommendations for the routine care of all women of reproductive age. Am J Obstet Gynecol2008; 199 (6): S280-S289.

16. Mazza D, Chapman A, Michie S. Barriers to the implementation of preconception care guidelines as perceived by general practitioners: a qualitative study. BMC Health Serv Res 2013; 13: 36.

17. Sprung VS, Atkinson G, Cuthbertson DJ, et al. Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: A meta-analysis of the observational studies. Clin Endocrinol (Oxf) 2013; 78: 438-46.

18. Moran LJ, Cameron JD, Strauss BJ, Teede HJ. Vascular function in the diagnostic categories of polycystic ovary syndrome. Hum Reprod. 2011; 26: 2192-2199.

19. Palomba S, Falbo A, Giallauria F, et al. Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. Diabetes Care 2010; 33: 246-251.

20. Rajendran S, Willoughby SR, Chan WP, et al. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis. 2009; 204: 509-514.

21. Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update. 2011; 17: 741-760.

22. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010; 95: 2038-2049.

23. Pepene CE. Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012; 76: 119-25.

24. Sprung VS, Jones H, Pugh CJ, et al. Endothelial dysfunction in hyperandrogenic polycystic ovary syndrome is not explained by either obesity or ectopic fat deposition. Clin Sci (Lond) 2014; 126:67-74.

25. Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018; 17: о121.

26. Muniyappa R, Sowers JR. Roles of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013; 14: 5-12.

27. Zhang X, McGeoch SC, Johnstone AM, et al. Platelet-derived micropar- ticle count and surface molecule expression differ between subjects with and without type 2 diabetes, independently of obesity status. J Thromb Thrombolysis. 2014;37:455-63.

28. Li H, Li H, Bao Y, Zhang X, Yu Y. Free fatty acids induce endothelial dysfunction and activate protein kinase C and nuclear factor-kB pathway in rat aorta. Int J Cardiol 2011; 152 (2): 218-224.

29. Mathew M, Tay E, Cusi K. Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. Cardiovasc Diabetol2010; 9: 9.

30. Kanasaki K, Palmsten K, Sugimoto H, et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature. 2008; 453 (7198): 1117-1121.

31. Bain E, Wilson A, Tooher R, Gates S, Davis LJ, Middleton P. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2014; 2: CD 001689.

32. Royal College of Obstetricians and Gynaecologist. Reducing the risk of venous Thromboembolism during Pregnancy and the Puerperium Green-to Guideline No. 37a, 2015; 40p.

33. Российское общество акушеров-гинекологов. Анестезия и интенсивная терапия у пациенток, получающих антикоагулянты для профилактики и лечения венозных тромбоэмболических осложнений в акушерстве. Клинические рекомендации (протокол лечения) МЗ РФ, 2018; 47 с.

34. Chighizola CB, Ubiali T, Meroni PL. Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management - An Insight into Future Approaches. J Immunol Res 2015; 2015: 951424.

35. Hoppensteadt DA, Fareed J. Pharmacological profile of sulodexide. Int Angiol 2014; 33 (3): 229-235.

36. Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther. 2013; 8: 49-65.

37. Masola V, Zaza G, Onisto M, et al. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects. Int Angiol. 2014; 33 (3): 243-254.

38. Karthikeyan VJ, Lip GY. Endothelial damage/ dysfunction and hypertension in pregnancy. Front Biosci. (Elite Ed). 2011; 1 (3): 1100-1108.

39. LaMarca B. Endothelial dysfunction; an important mediator in the Pathophysiology of Hypertension during Preeclampsia. Minerva Ginecol2012; 64 (4): 309-320.

40. Li T, Liu X, Zhao Z, et al. Sulodexide recovers endothelial function through reconstructing glycocalyx in the balloon-injury rat carotid artery model. Oncotarget2017; 8 (53): 91350-91361.

41. Eskens BJM, Vink H, VanTeeffelen. Improvement of Insulin Reistance in Diet-Induced Obese Mice by Sulodexide, an Endothelial Glycocalyx Mimetic. J Endocrinol Diabetes Obes 2014; 2 (2): 1027.

42. Broekhuizen LN, Lemkes BA, Mooij HL, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010; 53 (12): 2646-2655.

43. Gabryel B, Jarzabek K, Machnik G, et al. Superoxide dismutase 1 and glutathione peroxidase 1 are involved in the protective effect of sulodexide on vascular endothelial cells exposed to oxygen-glucose deprivation. Microvasc. Res2015; 103:26-35.

44. Попова Т.А., Перфилова В. Н., Жакупова Г. А. и соавт. Влияние сулодексида на функциональное состояние митохондрий плаценты самок крыс с экспериментальной преэклампсией. Биомедицинская химия 2016; 62 (5): 572-576.

45. Федоренко А. В., Дикке Г. Б. Плацентарная недостаточность у беременных с гестационной артериальной гипертензией и патогенетический подход к ее профилактике. Фарматека 2015; 3.

46. Olde Engberink RH, Rorije NM, Lambers Heerspink HJ, et al. The blood pressure lowering potential of sulodexide - a systematic review and meta-analysis. Br J Clin Pharmacol. 2015; 80 (6): 1245-1253.

47. Iozza I, Cianci S, Di Natale A, et al. Update on systemic lupus erythematosus pregnancy. J Prenat Med 2010; 4 (4): 67-73.

48. Щербаков А. Ю., Меликова Т. А. Мониторинг эффективности применения натурального антикоагулянта сулодексид у беременных с аутоиммунным гипертиреозом на фоне гипергомоцистеинемии. Патология. 2017; 14 (39): 57-56.

49. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of CVD in women - 2011 update. A guideline from the American Heart Association. Circulation 2011; 123 (11): 1243-1262.


Для цитирования:


Кузнецова И.В. Роль преконцепционной эндотелиальной дисфункции в развитии акушерских осложнений. Медицинский алфавит. 2019;1(1):53-58. https://doi.org/10.33667/2078-5631-2019-1-1(376)-53-58

For citation:


Kuznetsova I.V. Role ofpreconception endothelial dysfunction in development of obstetric complications. Medical alphabet. 2019;1(1):53-58. (In Russ.) https://doi.org/10.33667/2078-5631-2019-1-1(376)-53-58

Просмотров: 61


ISSN 2078-5631 (Print)